Get started
Author

Alice Garnier

Observed names: A Garnier, A. Garnier, Alice GARNIER, GARNIER, Alice, Garnier, Alice
Observed institutions: Karolinska University Hospital, Inserm, Aix-Marseille Université, Centre Hospitalier Universitaire de Lille, Centre Hospitalier Universitaire de Nice, Centre Hospitalier Universitaire de Nantes, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Antoine, Pitié-Salpêtrière Hospital, Centre Hospitalier Universitaire de Clermont-Ferrand, Conception de l'Action en Situation, Hôpital Saint-Louis, Hôpital de la Timone, Université Paris Diderot, Laboratoire d'hématologie, Université Pierre-et-Marie-Curie, Nantes Université
ORCID: 0000-0002-4461-6523
Observed ORCID: 0000-0002-4461-6523
OpenAlex ID: A5044090334
Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies
2012 · Gandhi Damaj, Alain Duhamel, et al. · Journal of Clinical Oncology · 210
PDF
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
2019 · Francine Garnache-Ottou, Chrystelle Vidal, et al. · Blood Advances · 122
PDF
Tumour lysis syndrome and acute kidney injury in high‐risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en R éanimation Respiratoire et O nco‐ H ématologique
2013 · Michael Darmon, François Vincent, et al. · British Journal of Haematology · 114
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome
2019 · Thierry Guillaume, Florent Malard, et al. · Bone Marrow Transplantation · 99
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX
2024 · Jerome Hadjadj, Yann Nguyen, et al. · Annals of the Rheumatic Diseases · 73
Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation
2018 · Christelle Retière, Catherine Willem, et al. · Oncotarget · 64
PDF
Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
2021 · Amandine Le Bourgeois, Marianne Coste-Burel, et al. · JAMA Network Open · 62
PDF
Chimerism analysis in peripheral blood using indel quantitative real-time PCR is a useful tool to predict post-transplant relapse in acute leukemia
2014 · N Jacque, S Nguyen, et al. · Bone Marrow Transplantation · 57
Deconditioning, fatigue and impaired quality of life in long-term survivors after allogeneic hematopoietic stem cell transplantation
2017 · Stéphanie Dirou, Arnaud Chambellan, et al. · Bone Marrow Transplantation · 51
PDF
Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide
2019 · Catherine Willem, Dhon Roméo Makanga, et al. · The Journal of Immunology · 48
Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome
2021 · Thierry Guillaume, Sylvain Thépot, et al. · Transplantation and Cellular Therapy · 47
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
2020 · Clara Sortais, Anne Lok, et al. · Annals of Hematology · 47
Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX
2025 · Vincent Jachiet, Olivier Kosmider, et al. · Blood · 41
PDF
Use of eltrombopag in aplastic anemia in Europe
2019 · for the EBMT SAA Working Party, Matyas Ecsedi, et al. · Annals of Hematology · 38
PDF
In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
2021 · Raynier Devillier, Edouard Forcade, et al. · Blood Advances · 35
PDF
Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
2021 · Patrice Chevallier, Marianne Coste‐Burel, et al. · eJHaem · 35
PDF
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study
2019 · Maxime Jullien, Sabrina Trudel, et al. · Annals of Hematology · 33
A novel complete blood count‐based score to screen for myelodysplastic syndrome in cytopenic patients
2018 · Robin Boutault, Pierre Peterlin, et al. · British Journal of Haematology · 33
Autologous hematopoietic stem cell transplantation in elderly patients (≥70years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study
2015 · E. Hermet, A. Cabrespine, et al. · Journal of Geriatric Oncology · 33
SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine
2022 · Béatrice Clémenceau, Thierry Guillaume, et al. · Vaccines · 29
PDF
Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy
2021 · Thomas Gastinne, Amandine Le Bourgeois, et al. · British Journal of Haematology · 29
PDF
Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution
2020 · Dhon Roméo Makanga, Thierry Guillaume, et al. · The Journal of Immunology · 28
Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
2010 · A. Garnier, M. Robin, et al. · Haematologica · 28
PDF
Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant
2021 · Amandine Le Bourgeois, Marianne Coste‐Burel, et al. · British Journal of Haematology · 26
PDF
Antithymocyte Globulin before Allogeneic Stem Cell Transplantation for Progressive Myelodysplastic Syndrome: A Study from the French Society of Bone Marrow Transplantation and Cellular Therapy
2014 · Rémy Duléry, Mohamad Mohty, et al. · Transplantation and Cellular Therapy · 26
PDF
Works count: 198
Citation count: 2,038
H-index: 25
I10-index: 55
Year
Topic
Type